GLP1R and Hyperglycemia: -Administered as a single dose of varying amounts (75 μg, 150 μg, 300 μg).—All doses prevented hypoglycemia but resulted in notable increases in postprandial hyperglycemia.-Pasireotide significantly diminished insulin, C-peptide, and GLP-1 responses.-The 75 μg dose appears sufficient to prevent hypoglycemia in RYGB-operated individuals with PBH, with reduced hyperglycemia compared to higher doses.